An antibody that binds the wrong target can waste months of experimental effort, generate irreproducible data, and lead to retracted publications. Yet antibody validation remains one of the most under-addressed aspects of experimental design — many researchers still rely solely on the supplier's datasheet without independent verification.
This guide covers five orthogonal strategies for validating antibody specificity, ranked from most definitive to most accessible. Whether you're validating a new antibody for a high-stakes publication, troubleshooting unexpected bands on a Western blot, or setting up a new IHC panel, at least two independent validation approaches should be applied before trusting your results.
Five Pillars of Antibody Validation
| Strategy |
Principle |
Strength |
Limitation |
Difficulty |
| 1. Genetic (KO/KD) |
Eliminate the target → signal should disappear |
Gold standard; definitive |
Requires KO cell line or siRNA; not always available |
High |
| 2. Orthogonal |
Compare antibody-based result with antibody-independent method |
Independent confirmation |
Requires mass spec, RNA-seq, or tagged protein |
Medium–High |
| 3. Independent Ab |
Two antibodies targeting different epitopes should give same result |
Practical; widely applicable |
Both may cross-react to same off-target |
Low–Medium |
| 4. Peptide/antigen competition |
Pre-incubate Ab with immunizing peptide → signal should be blocked |
Simple; confirms epitope binding |
Does not prove target specificity (only epitope specificity) |
Low |
| 5. Expression pattern |
Observed localization/expression matches published biology |
Easy; no extra reagents |
Circular reasoning; cannot discover novel expression |
Low |
The International Working Group for Antibody Validation (IWGAV) recommends using at least two of these five pillars — ideally including the genetic strategy when feasible — before relying on an antibody for publication-quality data (Uhlen et al., Nat Methods, 2016).
1. Genetic Validation: Knockout and Knockdown
Genetic validation is the most definitive approach because it directly tests the fundamental requirement of a specific antibody: if you remove the target protein, the antibody signal must disappear. Any residual signal in a KO/KD sample represents non-specific binding.
CRISPR Knockout (KO) Validation
Use a CRISPR-engineered cell line where the target gene is completely disrupted. Run the antibody on both wild-type (WT) and KO lysates/cells side by side. For WB, the target band must be absent in KO. For IHC/IF, the staining pattern must disappear in KO tissue or cells.
Many common targets now have commercially available KO cell lines (e.g., HEK293 KO, HeLa KO, Jurkat KO). Some antibody suppliers provide KO-validated antibodies with the KO data included on the datasheet. Always check whether the antibody you're purchasing has been validated against a KO control.
siRNA/shRNA Knockdown (KD) Validation
When a KO cell line is not available, transient knockdown with siRNA or stable knockdown with shRNA provides a partial genetic validation. The target protein band should be reduced (typically 70–90% knockdown) in the KD sample compared to the scrambled siRNA control.
Important caveat: siRNA knockdown rarely achieves 100% reduction. Residual band in the KD lane does not necessarily indicate non-specificity — it may simply reflect incomplete knockdown. Always verify knockdown efficiency at the mRNA level (qPCR) to distinguish between incomplete KD and non-specific antibody binding.
Also consider: Some proteins have long half-lives (days to weeks). Even with effective siRNA targeting the mRNA, pre-existing protein may persist. Allow sufficient time after siRNA transfection — 48–96 hours for most targets, longer for highly stable proteins.
2. Orthogonal Validation: Antibody-Independent Confirmation
Orthogonal validation compares the antibody-based measurement with a completely independent, antibody-free method. If both methods agree on expression levels across multiple samples, the antibody is likely detecting the correct target.
Common Orthogonal Approaches
| Antibody-Based Method |
Orthogonal Method |
What to Compare |
| WB band intensity across cell lines |
RNA-seq / qPCR mRNA expression |
Protein level should correlate with mRNA level across multiple cell lines |
| IHC staining pattern |
In situ hybridization (ISH) / single-cell RNA-seq |
Protein localization should match mRNA expression pattern |
| IP-MS (pull-down + mass spec) |
Tagged protein pull-down (GFP-trap, FLAG-IP) |
Same interactors should be identified by both approaches |
| Flow cytometry surface staining |
Reporter gene (GFP-tagged target) |
Antibody signal should correlate with GFP fluorescence |
Tip: Public databases like the Human Protein Atlas (proteinatlas.org), GTEx, and CCLE provide expression data across tissues and cell lines that you can use for orthogonal comparison without generating new data. If your antibody shows a WB band in a cell line where RNA-seq shows zero expression of the target, that band is almost certainly non-specific.
3. Independent Antibody Validation
If two antibodies raised against different epitopes of the same protein produce the same result (same WB band, same IHC staining pattern, same flow cytometry population), it is highly unlikely that both are showing the same off-target artifact. This approach does not require KO cell lines or special equipment — just a second antibody.
How to Implement
Select two antibodies that target different regions of the protein — ideally one against the N-terminus and one against the C-terminus, or one monoclonal and one polyclonal. Run both in parallel on the same sample set. Concordant results validate both antibodies; discordant results flag one or both as problematic.
| Antibody A Result |
Antibody B Result |
Interpretation |
| Band at 55 kDa |
Band at 55 kDa |
Concordant — both likely specific |
| Band at 55 kDa + extra band at 35 kDa |
Band at 55 kDa only |
The 55 kDa band is likely specific; the 35 kDa band from Ab A is non-specific |
| Band at 55 kDa |
Band at 70 kDa |
Discordant — at least one is wrong; investigate further |
4. Peptide/Antigen Competition (Blocking)
Pre-incubate the antibody with excess immunizing peptide or recombinant target protein before applying it to the sample. If the antibody is specific, the antigen will occupy all binding sites, and no signal should be detected on the sample.
Protocol
1. Prepare two aliquots of the antibody at working concentration.
2. To one aliquot, add a 5–10× molar excess of the immunizing peptide or recombinant protein. To the other, add an equal volume of buffer (negative control).
3. Incubate both at room temperature for 1 hour or 4°C overnight.
4. Apply both to identical samples (WB membrane, tissue section, cells) and process in parallel.
5. Compare: the peptide-blocked sample should show no signal or dramatically reduced signal.
Critical limitation: Peptide competition proves that the antibody binds the peptide it was raised against — but it does not prove that the antibody is specific for the target protein. If the immunizing peptide shares sequence homology with another protein, the antibody could cross-react, and competition would still block the signal. This is why peptide competition alone is considered the weakest validation strategy and should always be combined with at least one other approach.
5. Expression Pattern Validation
Compare the observed expression pattern (tissue distribution, subcellular localization, cell-type specificity) with published literature and public databases. If your anti-CD3 antibody stains epithelial cells and not T cells, something is wrong. If your anti-histone H3 antibody shows cytoplasmic staining instead of nuclear, the antibody is likely non-specific or the fixation protocol needs optimization.
Useful Resources for Expression Pattern Verification
| Resource |
Type |
Use |
| Human Protein Atlas (proteinatlas.org) |
IHC images + RNA expression |
Compare your IHC pattern with reference images across 44 human tissues |
| UniProt (uniprot.org) |
Protein annotation |
Check MW, subcellular localization, tissue distribution, known isoforms |
| GTEx Portal (gtexportal.org) |
RNA-seq across human tissues |
Verify tissue expression pattern at the mRNA level |
| CCLE / DepMap (depmap.org) |
Cell line expression data |
Identify positive and negative control cell lines for WB/FC validation |
Validation Is Application-Specific
A critical principle that many researchers overlook: an antibody validated for one application may not be specific in another. A monoclonal antibody that produces a clean, single band in WB (denatured, linear epitope) may show diffuse non-specific staining in IHC (native, conformational epitope) — or vice versa.
| Application |
Epitope State |
Validation Must Confirm |
| Western blot |
Denatured (linear) |
Single band at expected MW; absent in KO |
| IHC (FFPE) |
Fixed; partially denatured |
Expected tissue/cellular localization; no staining in KO tissue |
| IF / ICC |
Fixed; native or partially denatured |
Expected subcellular localization |
| Flow cytometry |
Native (surface); fixed (intracellular) |
Expected positive/negative populations; concordance with known markers |
| IP |
Native |
Pull-down of expected MW protein; confirmed by mass spec or WB with independent Ab |
| ChIP |
Cross-linked |
Enrichment at known target loci by qPCR; no enrichment at negative control loci |
Practical rule: Always validate the antibody in the same application, same species, and same sample type you plan to use it in. A datasheet showing WB validation in human HeLa cells does not guarantee performance in mouse brain tissue IHC.
Minimum Validation Checklist Before Publishing
☐ Correct molecular weight: Band appears at the expected MW on WB (check UniProt for predicted MW including known post-translational modifications).
☐ Positive control: Signal present in a sample known to express the target (e.g., HeLa for beta-actin, Jurkat for CD3).
☐ Negative control: No signal in a sample known to lack the target (e.g., CD3 antibody should not stain epithelial cell lines).
☐ KO/KD validation (if available): Signal absent or reduced in knockout/knockdown sample.
☐ At least one additional strategy: Independent antibody, orthogonal method, or peptide competition.
☐ Application-specific: Validation performed in the same application (WB, IHC, IF, FC, IP, ChIP) as your experiment.
Frequently Asked Questions
My antibody shows multiple bands on WB. Is it non-specific?
Not necessarily. Multiple bands can represent: splice variants or isoforms (check UniProt for known isoforms), post-translational modifications (glycosylation increases apparent MW; phosphorylation can cause shifts), proteolytic degradation products, or genuine non-specific bands. Run a KO/KD control to distinguish: bands that disappear in KO are target-related; bands that persist are non-specific.
Is "knockout validated" on a datasheet enough?
It is a strong starting point, but you should verify that the KO validation was done in the same application you plan to use. A KO-validated WB antibody may still require separate validation for IHC or FC. Also check whether the KO cell line used is relevant — a KO in HEK293 does not guarantee performance in primary mouse neurons.
How do I validate an antibody for a novel or poorly characterized target?
When KO cell lines and expression data are not available, focus on: (1) overexpression — transfect cells with a tagged version of your target and confirm the antibody detects it; (2) independent antibody comparison — use two antibodies from different suppliers targeting different epitopes; (3) mass spectrometry — pull down with the antibody and identify the captured protein by LC-MS/MS.
Do recombinant antibodies require less validation than polyclonals?
Recombinant antibodies offer better lot-to-lot reproducibility (defined sequence, no batch variation), but they still require validation for specificity in each application. The advantage is that once validated, a recombinant antibody will perform consistently across all future lots — unlike polyclonals, where each new bleed may differ.
Looking for Application-Validated Antibodies?
abinScience provides 22,000+ antibodies with application-specific validation data across WB, IHC, IF, ELISA, and flow cytometry. Each product page includes tested applications, species reactivity, and representative data.
Browse Validated Antibodies →
References
- Uhlen M, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(10):823-827. doi: 10.1038/nmeth.3995
- Bhatt DK, et al. Antibody validation: a key step for reproducible and reliable research. J Biol Chem. 2021;296:100438. doi: 10.1016/j.jbc.2021.100438
- Weller MG. Ten basic rules of antibody validation. Anal Chem Insights. 2018;13:1177390118757462. doi: 10.1177/1177390118757462
- Bordeaux J, et al. Antibody validation. BioTechniques. 2010;48(3):197-209. doi: 10.2144/000113382
中文
English
한국어
日本語
Español
Français
Русский
